1887

Abstract

SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019 (COVID-19). As of 17 April 2020, it has infected 2 114 269 people, resulting in 145 144 deaths. The timing, magnitude and longevity of humoral immunity is not yet understood for SARS-CoV-2. Nevertheless, understanding this is urgently required to inform the likely future dynamics of the pandemic, to guide strategies to allow relaxation of social distancing measures and to understand how to deploy limiting vaccine doses when they become available to achieve maximum impact. SARS-CoV-2 is the seventh human coronavirus to be described. Four human coronaviruses circulate seasonally and cause common colds. Two other coronaviruses, SARS and MERS, have crossed from animal sources into humans but have not become endemic. Here we review what is known about the human humoral immune response to epidemic SARS CoV and MERS CoV and to the seasonal, endemic coronaviruses. Then we summarize recent, mostly non-peer reviewed, studies into SARS-CoV-2 serology and reinfection in humans and non-human primates and summarize current pressing research needs.

Funding
This study was supported by the:
  • , This work received no specific grant from a funding agency.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001439
2020-05-20
2020-06-03
Loading full text...

Full text loading...

/deliver/fulltext/jgv/10.1099/jgv.0.001439/jgv001439.html?itemId=/content/journal/jgv/10.1099/jgv.0.001439&mimeType=html&fmt=ahah

References

  1. Choe PG, Perera RAPM, Park WB, Song K-H, Bang JH et al. Mers-Cov antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis 2017; 23: 1079 1084 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  2. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis 2016; 22: [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  3. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A et al. Persistence of antibodies against middle East respiratory syndrome coronavirus. Emerg Infect Dis 2016; 22: 1824 1826 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  4. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E et al. Sensitive and specific detection of low-level antibody responses in mild middle East respiratory syndrome coronavirus infections. Emerg Infect Dis 2019; 25: 1868 1877 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  5. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014; 371: 828 835 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  6. Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 2007; 357: 1162 1163 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  7. Mo H, Zeng G, Ren X, Li H, Ke C et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 2006; 11: 49 53 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  8. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis 2007; 13: 1562 1564 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  9. Liu W, Fontanet A, Zhang P-H, Zhan L, Xin Z-T et al. Two-Year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 2006; 193: 792 795 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  10. Liu L, Xie J, Sun J, Han Y, Zhang C et al. Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis 2011; 43: 515 521 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  11. Guo X, Guo Z, Duan C, chen Z, Wang G et al. Long-Term persistence of IgG antibodies in SARS-CoV infected healthcare workers. medRxiv 2020
    [Google Scholar]
  12. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Müller MA et al. Human coronavirus NL63 and 229E seroconversion in children. J Clin Microbiol 2008; 46: 2368 2373 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  13. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol 2020; 92: 512 517 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  14. Ambrosioni J, Bridevaux P-O, Wagner G, Mamin A, Kaiser L. Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva, Switzerland, 2011-2012. Clin Microbiol Infect 2014; 20: O578 O584 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  15. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res 2007; 38: 281 297 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  16. Vijgen L, Keyaerts E, Lemey P, Moës E, Li S et al. Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology 2005; 337: 85 92 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  17. Ren L, Zhang Y, Li J, Xiao Y, Zhang J et al. Genetic drift of human coronavirus OC43 spike gene during adaptive evolution. Sci Rep 2015; 5: 11451 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  18. Kiyuka PK, Agoti CN, Munywoki PK, Njeru R, Bett A et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J Infect Dis 2018; 217: 1728 1739 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  19. Aldridge RW, Lewer D, Beale S, Johnson AM, Zambon M et al. Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the flu watch cohort study. Wellcome Open Res 2020; 5: 52 [CrossRef]
    [Google Scholar]
  20. Dijkman R, Jebbink MF, Gaunt E, Rossen JWA, Templeton KE et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J Clin Virol 2012; 53: 135 139 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  21. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020 eabb5793 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  22. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect 1990; 105: 435 446 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  23. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers. J Med Virol 1984; 13: 179 192
    [Google Scholar]
  24. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv 2020
    [Google Scholar]
  25. Adams ER, Anand R, Andersson M I, Auckland K et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. medRxiv 2020
    [Google Scholar]
  26. Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv 2020
    [Google Scholar]
  27. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and seroprevalence testing in Idaho. medRxiv 2020
    [Google Scholar]
  28. Lipsitch M, Kahn R, Mina MJ. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. Nat Med 2020 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  29. Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B et al. Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Rev Vaccines 2010; 9: 73 87 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  30. Zhao J, Yuan Q, Wang H, Liu W, Liao X et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  31. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020a; 62: [CrossRef]
    [Google Scholar]
  32. Lou B, Li T, Zheng S, Su Y, Li Z et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv 2020
    [Google Scholar]
  33. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv 2020
    [Google Scholar]
  34. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 382: [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  35. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020; 26: 453 455 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  36. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20: 565 574 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  37. Wu F, Wang A, Liu M, Wang Q, Chen J et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications.. medRxiv 2020
    [Google Scholar]
  38. Thompson C, Grayson N, Paton R, Lourenço J, Penman B et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure. medRxiv 2020
    [Google Scholar]
  39. Quinlan BD, Mou H, Zhang L, Guo Y, He W et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. SSRN Journal 2020 [CrossRef]
    [Google Scholar]
  40. Chen H. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2. BioRxiv 2020
    [Google Scholar]
  41. Kim Y-I, Kim S-G, Kim S-M, Kim E-H, Park S-J et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 2020 [CrossRef] [PubMed] [PubMed]
    [Google Scholar]
  42. Munster V, Feldmann F, Williamson B, van Doremalen N, Perez-Perez L et al. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. BioRxiv 2020
    [Google Scholar]
  43. Bao L, Deng W, Gao H, Xiao C et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. BioRxiv 2020
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001439
Loading
/content/journal/jgv/10.1099/jgv.0.001439
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error